- Home
- CRBP vs MSW Comparison
CRBP vs MSW Comparison
Compare CRBP & MSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- MSW
- Stock Information
- Founded
- CRBP 2009
- MSW 2012
- Country
- CRBP United States
- MSW Hong Kong
- Employees
- CRBP N/A
- MSW N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- MSW
- Sector
- CRBP Health Care
- MSW
- Exchange
- CRBP Nasdaq
- MSW NYSE
- Market Cap
- CRBP 73.4M
- MSW N/A
- IPO Year
- CRBP N/A
- MSW 2024
- Fundamental
- Price
- CRBP $5.03
- MSW $3.84
- Analyst Decision
- CRBP Strong Buy
- MSW
- Analyst Count
- CRBP 10
- MSW 0
- Target Price
- CRBP $60.89
- MSW N/A
- AVG Volume (30 Days)
- CRBP 211.7K
- MSW 52.7K
- Earning Date
- CRBP 03-11-2025
- MSW 05-25-2025
- Dividend Yield
- CRBP N/A
- MSW N/A
- EPS Growth
- CRBP N/A
- MSW 18.78
- EPS
- CRBP N/A
- MSW 0.20
- Revenue
- CRBP N/A
- MSW $31,769,612.00
- Revenue This Year
- CRBP N/A
- MSW N/A
- Revenue Next Year
- CRBP $270.01
- MSW N/A
- P/E Ratio
- CRBP N/A
- MSW $17.57
- Revenue Growth
- CRBP N/A
- MSW 30.91
- 52 Week Low
- CRBP $4.92
- MSW $2.12
- 52 Week High
- CRBP $61.90
- MSW $10.58
- Technical
- Relative Strength Index (RSI)
- CRBP 25.32
- MSW N/A
- Support Level
- CRBP $5.76
- MSW N/A
- Resistance Level
- CRBP $6.17
- MSW N/A
- Average True Range (ATR)
- CRBP 0.40
- MSW 0.00
- MACD
- CRBP 0.01
- MSW 0.00
- Stochastic Oscillator
- CRBP 5.33
- MSW 0.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.